AbbVie (NYSE:ABBV) Stock Rating Upgraded by Leerink Partnrs

AbbVie (NYSE:ABBV) was upgraded by analysts at Leerink Partnrs from a “hold” rating to a “strong-buy” rating in a report released on Friday,Zacks.com reports. Leerink Partnrs also issued estimates for AbbVie’s FY2026 earnings at $13.69 EPS, FY2027 earnings at $15.36 EPS and FY2028 earnings at $16.79 EPS.

Other research analysts have also issued research reports about the company. Bank of America lifted their target price on AbbVie from $185.00 to $195.00 and gave the company a “neutral” rating in a report on Friday, October 18th. UBS Group lifted their target price on AbbVie from $195.00 to $200.00 and gave the company a “neutral” rating in a report on Thursday, October 31st. Leerink Partners raised AbbVie from a “market perform” rating to an “outperform” rating and set a $206.00 target price for the company in a report on Friday. Sanford C. Bernstein assumed coverage on AbbVie in a report on Thursday, October 17th. They set a “market perform” rating and a $203.00 target price for the company. Finally, Wells Fargo & Company lifted their target price on AbbVie to $195.00 and gave the company a “buy” rating in a report on Tuesday, November 19th. Three analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $203.50.

AbbVie Trading Up 3.0 %

Shares of AbbVie stock opened at $176.95 on Friday. AbbVie has a 52-week low of $137.65 and a 52-week high of $207.32. The stock’s 50-day simple moving average is $189.47 and its 200 day simple moving average is $181.17. The stock has a market capitalization of $312.70 billion, a P/E ratio of 61.44, a P/E/G ratio of 2.09 and a beta of 0.63. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.54 and a current ratio of 0.65.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $3.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.92 by $0.08. AbbVie had a return on equity of 244.01% and a net margin of 9.22%. The business had revenue of $14.46 billion for the quarter, compared to analysts’ expectations of $14.28 billion. During the same period in the previous year, the business posted $2.95 EPS. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. As a group, research analysts anticipate that AbbVie will post 10.95 EPS for the current year.

Institutional Trading of AbbVie

Hedge funds and other institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. bought a new position in shares of AbbVie during the first quarter valued at approximately $646,000. Quent Capital LLC raised its holdings in shares of AbbVie by 3.3% during the first quarter. Quent Capital LLC now owns 8,740 shares of the company’s stock valued at $1,592,000 after acquiring an additional 283 shares in the last quarter. Lavaca Capital LLC raised its holdings in shares of AbbVie by 22.5% during the first quarter. Lavaca Capital LLC now owns 7,601 shares of the company’s stock valued at $1,384,000 after acquiring an additional 1,396 shares in the last quarter. Zurich Insurance Group Ltd FI raised its holdings in shares of AbbVie by 110.4% during the first quarter. Zurich Insurance Group Ltd FI now owns 719,135 shares of the company’s stock valued at $130,954,000 after acquiring an additional 377,299 shares in the last quarter. Finally, Kinloch Capital LLC grew its stake in AbbVie by 7.1% in the first quarter. Kinloch Capital LLC now owns 19,065 shares of the company’s stock worth $3,472,000 after purchasing an additional 1,260 shares during the period. Institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.